Leukemia Myelogenous Chronic Bcr-abl Positive
📧 Sign up to get email alerts when something new happens for Leukemia Myelogenous Chronic Bcr-abl Positive.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-07EMA Authorised: Scemblix (asciminib hydrochloride) — Novartis Europharm Limited
EMA authorised Scemblix (asciminib hydrochloride) for chronic myeloid leukemia with BCR-ABL positive status.
-
EMA approval · 2026-07-20EMA Authorised: Scemblix (asciminib hydrochloride) — Novartis Europharm Limited
Scemblix (asciminib hydrochloride) has been authorised in the EU for chronic myeloid leukemia positive for BCR-ABL, with orphan designation.
-
EMA approval · 2025-05-06EMA Authorised: Imatinib Accord (imatinib) — Accord Healthcare S.L.U.
The EMA authorised Imatinib Accord (imatinib) for several indications, including Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dermatofibr…